Clinical subtypes for breast cancer are based on the immunohistochemical (IHC) determination of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [2, 3]. This evidence concerns the gene ERBB2 and breast carcinoma.